Eli Lilly and Company
NYSE:LLY Stock Report
Eli Lilly Balance Sheet Health
Financial Health criteria checks 3/6 Eli Lilly has a total shareholder equity of $14.3B and total debt of $31.2B, which brings its debt-to-equity ratio to 218.1%. Its total assets and total liabilities are $75.6B and $61.3B respectively. Eli Lilly's EBIT is $14.9B making its interest coverage ratio 28.7. It has cash and short-term investments of $3.5B.
Key information
218.1%
Debt to equity ratio
Interest coverage ratio 28.7x Cash US$3.52b Equity US$14.32b Total liabilities US$61.29b Total assets US$75.61b
Recent financial health updates
Show all updates Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting Nov 05
Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium Nov 02
Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next Nov 01
Third quarter dividend of US$1.30 announced Nov 01 Eli Lilly and Company Revises Earnings Guidance for the Year 2024 Oct 30
Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges Oct 30 Eli Lilly and Company Announces Positive Results from the TRAILBLAZER-ALZ 6 Phase 3B Study Oct 30
Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease Oct 29
Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024 Oct 28
Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab Oct 26
Eli Lilly Buy On Weakness Signal (Technical Analysis) Oct 20
Consensus EPS estimates fall by 18% Oct 16 Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease Oct 14
Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024 Oct 10
Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis Sep 30
Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade) Sep 20
Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth Sep 18 FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis Sep 14
Eli Lilly and Co. Appoints Lucas Montarce as CFO Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa Sep 05
Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside Sep 04
Eli Lilly: Tirzepatide's Winning Streak Continues Aug 20 Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide Aug 20
Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024 Aug 17
Price target increased by 7.4% to US$989 Aug 16 Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others. Aug 16
Consensus EPS estimates increase by 16% Aug 15
Price target increased by 7.2% to US$987 Aug 14
Eli Lilly Triggers Our Confirmed Buy Signal (Technical Analysis) Aug 12
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 09 Eli Lilly and Company Raises Earnings Guidance Full-Year 2024 Aug 08
Upcoming dividend of US$1.30 per share Aug 08
Eli Lilly: I Expect Strong Q2 Earnings, But The Valuation Is Already Optimistic Aug 04 Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024 Jul 25
Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China Jul 25
A Look At The Fair Value Of Eli Lilly and Company (NYSE:LLY) Jul 16 Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion. Jul 08
Wall Street Lunch: Merger Monday In All Its Glory Jul 08 Eli Lilly and Company(NYSE:LLY) dropped from Russell 1000 Growth-Defensive Index
5 Reasons Eli Lilly Just Keeps Rising Jun 30
Financial Position Analysis
Short Term Liabilities: LLY's short term assets ($31.4B) exceed its short term liabilities ($24.7B).
Long Term Liabilities: LLY's short term assets ($31.4B) do not cover its long term liabilities ($36.6B).
Debt to Equity History and Analysis
Debt Level: LLY's net debt to equity ratio (193.5%) is considered high .
Reducing Debt: LLY's debt to equity ratio has reduced from 442.1% to 218.1% over the past 5 years.
Debt Coverage: LLY's debt is not well covered by operating cash flow (19.3%).
Interest Coverage: LLY's interest payments on its debt are well covered by EBIT (28.7x coverage).
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
